Crossmark

Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning

Crossref DOI link: https://doi.org/10.1007/s00259-018-4044-x

Published Online: 2018-05-21

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cremonesi, Marta

Ferrari, Mahila Esmeralda

Bodei, Lisa

Chiesa, Carlo

Sarnelli, Anna

Garibaldi, Cristina

Pacilio, Massimiliano

Strigari, Lidia

Summers, Paul Eugene

Orecchia, Roberto

Grana, Chiara Maria

Botta, Francesca
License Information

Text and Data Mining valid from 2018-05-21
More Information

Article History

Received: 4 December 2017

Accepted: 27 April 2018

First Online: 21 May 2018

Compliance with ethical standards

:

: L.B. acted as a consultant for Advanced Accelerator Applications (AAA) and Ipsen, and has received speaker honorarium from AAA, for work not related to the present paper.C.C. was a consultant for Alfasigma and discloses funding from BTG Biocompatibles for work not related to the present paper.M.P. was a consultant for Bayer Healthcare Pharmaceuticals Inc. as a member of the Targeted Alpha Therapy Working Group Advisory Board.M.C., M.E.F., A.S., C.G., L.S., P.E.S., R.O., C.M.G. and F.B. declare that they have no conflicts of interest.

: This article does not contain any studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below